# A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors

> **NCT05394168** · PHASE1 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 12 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** HLX53

## Key facts

- **NCT ID:** NCT05394168
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-09
- **Primary completion:** 2024-12-04
- **Final completion:** 2025-03-04
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394168, "A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05394168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*